Ulcerative Colitis
📧 Sign up to get email alerts when something new happens for Ulcerative Colitis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Hulio (adalimumab) biosimilar with approvals across multiple inflammatory indications.
-
EMA approval · 2026-08-24EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) for multiple inflammatory diseases including rheumatoid arthritis and Crohn's disease.
-
EMA approval · 2026-08-18EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
Amgevita (adalimumab) by Amgen Europe B.V. has been authorised by the EMA for multiple inflammatory diseases including arthritis, psoriatic …
-
EMA approval · 2026-08-18EMA Authorised: Stelara (ustekinumab) — Janssen-Cilag International NV
EU authorises Stelara (ustekinumab) for multiple indications including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colit…
-
CLINICAL_TRIALS trial_result · 2026-08-12Clinical Trial Results: Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis [NA]
Completed clinical trial evaluating intestinal ultrasound for pouchitis and related outcomes after ileal pouch-anal anastomosis in ulcerativ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-11EMA Authorised: Usgena (ustekinumab) — Stada Arzneimittel AG
Stada Arzneimittel AG authorized to market Usgena (ustekinumab) for Crohn's disease, psoriasis, psoriatic arthritis, and ulcerative colitis …
-
EMA approval · 2026-08-06EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) from Fresenius Kabi Deutschland for multiple inflammatory diseases including rheuma…
-
EMA approval · 2026-08-05EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Humira (adalimumab) for multiple inflammatory diseases across indications, confirming market authorization.
-
EMA withdrawal · 2026-07-31EMA Withdrawn: Qoyvolma (ustekinumab) — Celltrion Healthcare Hungary Kft.
The EMA has withdrawn Qoyvolma (ustekinumab) from the market.
-
EMA approval · 2026-07-30EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
Biosimilar adalimumab (Hulio) has been authorised by EMA for multiple indications including hidradenitis suppurativa, psoriasis, uveitis, rh…
-
EMA approval · 2026-07-21EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
Authorised status for Gobivaz (golimumab) by Advanz Pharma Limited for multiple inflammatory diseases, expanding label in Europe.
-
EMA approval · 2026-07-17EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EU authorization of Hukyndra (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including rheumatoid arthritis and inf…
-
EMA approval · 2026-07-15EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
Rinvoq (upadacitinib) has been authorised by the EMA for multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthritis,…
-
EMA approval · 2026-07-13EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
Authorised status for Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory and autoimmune diseases.
-
EMA approval · 2026-07-13EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) for multiple inflammatory diseases, expanding the portfolio under Fresenius Kabi De…
-
EMA approval · 2026-07-03EMA Authorised: Pyzchiva (ustekinumab) — Samsung Bioepis NL B.V.
EU authorization of Pyzchiva (ustekinumab) for Crohn's disease, ulcerative colitis, and psoriatic arthritis.
-
EMA approval · 2026-07-01EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
European Medicines Agency authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including various form…
-
EMA approval · 2026-06-25EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
EU authorisation of Skyrizi (risankizumab) for multiple inflammatory diseases including psoriasis, psoriatic arthritis, ulcerative colitis, …
-
CLINICAL_TRIALS trial_result · 2026-06-23Clinical Trial Results: Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis [Phase 2]
Phase 2 trial results for OSE-127 versus placebo in moderate to severe active ulcerative colitis were completed and results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-23Clinical Trial Results: ENhanced Recovery in CHildren Undergoing Surgery [Phase 3]
Phase 3 trial results for enhanced recovery in children undergoing surgery for inflammatory bowel disease, including Crohn's disease and ulc…
-
CLINICAL_TRIALS trial_result · 2026-06-23Clinical Trial Results: Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 2]
A phase 2 placebo-controlled trial of brazikumab in moderately to severely active ulcerative colitis was terminated; results were posted aft…
-
CLINICAL_TRIALS trial_result · 2026-06-23Clinical Trial Results: Open-label Extension Study of Brazikumab in Ulcerative Colitis [Phase 2]
Open-label extension study results for brazikumab in ulcerative colitis (Phase 2) have been terminated with results posted.
-
EMA approval · 2026-06-15EMA Authorised: Entyvio (vedolizumab) — Takeda Pharma A/S
EMA authorises Entyvio (vedolizumab) for use in ulcerative colitis and Crohn's disease with Takeda as MAH.
-
CLINICAL_TRIALS trial_result · 2026-06-15Clinical Trial Results: Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis [Phase 2]
Phase 2 trial evaluating oral NX-13 for moderate to severe ulcerative colitis has been terminated with results posted.
-
EMA approval · 2026-06-09EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
EU authorization of Rinvoq (upadacitinib) by AbbVie Deutschland for multiple inflammatory indications including rheumatoid arthritis, psoria…